Scribe Therapeutics, Inc.
SCTX Nasdaq
SEC CIK 1853921
Follow Scribe Therapeutics
Weekly email: filings, results
Revenue, last quarter
$1.6M
−91.9% vs same quarter last year
Net income
−$9.9M
−770% vs same quarter last year
EPS, diluted
−$0.68
Operating cash flow
−$11.3M
+0.4% vs same quarter last year
Source: SEC XBRL filings · latest filing